Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 3 - Chemotherapy in the treatment of pregnant women with cancer

  • from SECTION 1 - Epidemiology, Genetics and Basic Principles of Chemotherapy and Radiotherapy
  • Edited by Sean Kehoe, Eric Jauniaux, Pierre Martin-Hirsch, Philip Savage
  • Book:
    Cancer and Reproductive Health
    Published online:
    05 October 2014
    Print publication:
    01 November 2008, pp 23-54

  • Summary

    A number of key issues must be considered regarding the treatment of a malignancy in pregnancy. The optimal dosing of chemotherapy during pregnancy is an important issue that requires consideration as the blood volume is 50% higher in pregnant women. The main adverse effect from dose-dense chemotherapy is neutropenia, which in nonpregnant patients is frequently managed by the use of granulocyte colony stimulating factor (G-CSF). Antimetabolites are small, weakly acidic molecules used to treat leukaemia, lymphoma and breast cancer. The concentrations in milk are variable and related to the dose and timing of chemotherapy and all standard advice is that breastfeeding is contraindicated while undergoing chemotherapy. The maternal benefits of receiving chemotherapy before delivery must outweigh the fetal risks of exposure and the maternal risk of delaying treatment until after delivery at a gestational age optimal for both fetal survival and wellbeing.